Turfan, Xinjiang: Electricity Ensures Steady Development of a 3-Billion-Yuan Energy Hub
TURFAN, China, June 24, 2025 /PRNewswire/ -- On June 24, the temporary construction phase of the No. 1 Open-Pit Mine in the Kumtag Mining Area, located in Shanshan County, Turfan City, Xinjiang, officially commenced. This marks the entry of this key...
Forum held to promote cooperation between China, Central Asia news agencies
ASTANA, Kazakhstan, June 24, 2025 /PRNewswire/ -- This is a report from Xinhuanet: President of Xinhua News Agency Fu Hua attends the China-Central Asia News Agency Forum in Astana, Kazakhstan, June 22, 2025. The China-Central Asia News Agency Forum...
IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)
SHANGHAI and NANJING, China and SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and...
SNEC 2025｜Hithium Defines a New Benchmark for Energy Storage Safety with the World's First All Open-Door Large-Scale Fire Test
SHANGHAI, June 13, 2025 /PRNewswire/ -- On June 11, 2025, at the 18th SNEC, Hithium, a leading global energy storage technology company, held a product safety technology sharing event themed Leading the Future, Forged for Safety and unveiled the...
XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
SUZHOU, China, June 3, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven...
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
YANTAI, China, June 3, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating...
Japan Airlines Selects IFS Cloud to Power Global Aviation Maintenance
Japan's flagship carrier transitions from legacy vendor to IFS Cloud to support long-term transformation with aviation maintenance and enterprise capabilities TOKYO, June 2, 2025 /PRNewswire/ -- IFS, the leading provider of enterprise cloud and...
InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025
NANJING, China, June 1, 2025 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; NCT05379946)...
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...
May 19: World Inflammatory Bowel Disease Day | Healthy Gut, Happy Life
SHENZHEN, China, May 26, 2025 /PRNewswire/ -- May 19 is designated as World Inflammatory Bowel Disease (IBD) Day, aimed at raising public awareness of IBD patients and improving their quality of life and medical care. The European Federation of...